Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Stereotactic Body Radiation and Monoclonal Antibody to OX40 (MEDI6469) in Breast Cancer Patients With Metastatic Lesions (OX40 Breast)

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2016 by Providence Health & Services
Sponsor:
Collaborators:
Robert W. Franz Cancer Center
Providence Cancer Center
Providence Cancer Center, Earle A. Chiles Research Institute
MedImmune LLC
Information provided by (Responsible Party):
Providence Health & Services
ClinicalTrials.gov Identifier:
NCT01862900
First received: May 22, 2013
Last updated: June 23, 2016
Last verified: June 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: February 2023
  Estimated Primary Completion Date: February 2018 (Final data collection date for primary outcome measure)